About Epsilogen

Epsilogen discovers and develops immunoglobulin IgE, IgA and IgG based antibody therapeutics for cancer. The company matches the unique immune effector functions of each antibody isotype to specific cancer types to maximize performance. Its lead candidate, MOv18 IgE, is the world's first therapeutic IgE antibody to enter clinical trials, targeting folate receptor alpha in platinum resistant ovarian cancer patients. The company's proprietary platforms leverage differential capabilities of antibody isotypes, including IgE's enhanced tumour access and ability to activate both myeloid and T cells. Epsilogen serves patients with solid tumours including ovarian, lung, endometrial and triple negative breast cancer through its clinical pipeline.